加载中
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
前收盘价
US$7.16
+US$0.19 · +2.73%
盘中时间采用ET。市场数据可能有所延迟。
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
日内区间
当前US$7.16
52周区间
当前US$7.16
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
34
偏贵
情绪
58
多空交织
风险
39
中等风险
动量
72
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
日内区间
当前US$7.16
52周区间
当前US$7.16
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 营收 | 2405万 USD | — | — | — |
| 销货成本 | 349.6万 USD | 315.2万 USD | — | 25万 USD |
| 毛利 | 2055.4万 USD | −315.2万 USD | — | −25万 USD |
| 研究与开发 | 3.86亿 USD | 2.66亿 USD | 1.38亿 USD | 1.01亿 USD |
| 销售、一般及管理费用 | 9185.6万 USD | 3520万 USD | 2049.8万 USD | 1254.6万 USD |
| 营业费用 | 4.48亿 USD | 2.98亿 USD | 1.58亿 USD | 1.14亿 USD |
| 利息收入 | 1418万 USD | 1202万 USD | 336.8万 USD | 199.2万 USD |
| 折旧和摊销 | 349.6万 USD | 315.2万 USD | 128.4万 USD | 25万 USD |
| 营业利润 | −4.27亿 USD | −3.01亿 USD | −1.58亿 USD | −1.14亿 USD |
| 净利润 | −2.43亿 USD | −2.94亿 USD | −1.55亿 USD | −1.12亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6866.81万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF2160.84万0.02%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 ETFIWM1442.06万0.02%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO989.81万0.05%180亿 USD0.06%US$112.66+0.50%
State Street SPDR S&P Pharmaceuticals ETFXPH667.03万1.45%4.62亿 USD0.35%US$64.65+1.60%
iShares Biotechnology ETFIBB520.42万0.05%108.2亿 USD0.44%US$206.49+3.00%
iShares Russell 2000 Growth ETFIWO511.45万0.04%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Health Care ETFVHT390.39万0.02%220亿 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
